Globus Medical, Inc. (GMED) A Cheap Robotics Stock Firing on Earnings and Revenue Growth

The awesome results were characterized by 27% wide gross maturation and grounds earnings. Organic gross was up 13%, driven by stock gains and procedural measurement spot successful halfway spine. Consequently, worldwide revenues totaled $759.9 million, arsenic basal concern nett income excluding Nevro totaled $677.2 million.

Robust gross maturation came arsenic Globus Medical’s Musculoskeletal Solutions and Enabling Tech segments achieved broad-based maturation successful the quarter. Revenue successful the Spine transmission was up 10%, marking the 3rd consecutive 4th of 10% growth. Net income successful the 4th totaled $124.3 cardinal arsenic diluted net per stock accrued 64.7% to $1.12.

Earnings bushed estimates by 22%, driven by higher sales. International Spine gross was besides up by 10%. For the afloat year, Globus Medical expects gross to scope betwixt $3.18 cardinal and $3.33 billion. It has besides updated its non-GAAP diluted EPS to betwixt $4.70 and $4.80, up from the erstwhile guidance of $4.40 to $4.50.

Globus Medical, Inc. (NYSE:GMED) develops precocious surgical robotics and navigation platforms designed to amended the accuracy, safety, and ratio of orthopedic, spinal, and cranial procedures. Their exertion acts arsenic a “third hand” for surgeons, combining rigid robotic arms with real-time tracking.

While we admit the imaginable of GMED arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 10 Best Sin Stocks to Buy Now and 8 Best CBD Stocks to Buy Right Now.

Disclosure: None. Follow Insider Monkey connected Google News.